Estrella Immunopharma, Inc. (ESLA)
0.39
-0.02
(-4.90%)
USD |
NASDAQ |
Nov 06, 09:59
Estrella Immunopharma Debt to Equity Ratio : 0.00 for June 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.00 |
| March 31, 2026 | 0.00 |
| December 31, 2025 | 0.00 |
| September 30, 2025 | 0.00 |
| June 30, 2025 | 0.00 |
| March 31, 2025 | 0.00 |
| December 31, 2024 | 0.00 |
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | 0.00 |
| Date | Value |
|---|---|
| September 30, 2023 | 0.0298 |
| June 30, 2023 | 0.1344 |
| March 31, 2023 | 0.1049 |
| December 31, 2022 | 0.0705 |
| September 30, 2022 | 0.0115 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 8.738 |
| February 28, 2021 | 4.132 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.0413 |
| Alnylam Pharmaceuticals, Inc. | 0.8316 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
| Vericel Corp. | 0.2556 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 1.825M |
| Total Liabilities (Quarterly) | 9.256M |
| Shareholders Equity (Quarterly) | -7.431M |
| Current Ratio | 0.1971 |